BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37114557)

  • 1. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
    Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
    Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
    Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation.
    Liu H; Sun Q; Sun Y; Zhang J; Yuan H; Pang S; Qi X; Wang H; Zhang M; Zhang H; Yu C; Gu C
    Mol Cancer Res; 2017 Sep; 15(9):1275-1286. PubMed ID: 28536141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastoma.
    Natsumeda M; Liu Y; Nakata S; Miyahara H; Hanaford A; Ahsan S; Stearns D; Skuli N; Kahlert UD; Raabe EH; Rodriguez FJ; Eberhart CG
    Neuropathology; 2019 Apr; 39(2):71-77. PubMed ID: 30632221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the enhancer of zeste homologue 2 in medulloblastoma.
    Alimova I; Venkataraman S; Harris P; Marquez VE; Northcott PA; Dubuc A; Taylor MD; Foreman NK; Vibhakar R
    Int J Cancer; 2012 Oct; 131(8):1800-9. PubMed ID: 22287205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling medulloblastoma in vivo and with human cerebellar organoids.
    Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
    Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma.
    Huq S; Kannapadi NV; Casaos J; Lott T; Felder R; Serra R; Gorelick NL; Ruiz-Cardozo MA; Ding AS; Cecia A; Medikonda R; Ehresman J; Brem H; Skuli N; Tyler BM
    J Neurosurg Pediatr; 2021 Feb; 27(4):482-488. PubMed ID: 33545678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway.
    Zhang H; Zhu D; Zhang Z; Kaluz S; Yu B; Devi NS; Olson JJ; Van Meir EG
    Oncogene; 2020 Jan; 39(5):1041-1048. PubMed ID: 31582835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression.
    Wolin AR; Vincent MY; Hotz T; Purdy SC; Rosenbaum SR; Hughes CJ; Hsu JY; Oliphant MUJ; Armstrong B; Wessells V; Varella-Garcia M; Galbraith MD; Pierce A; Wang D; Venkataraman S; Danis E; Veo B; Serkova N; Espinosa JM; Gustafson DL; Vibhakar R; Ford HL
    Neuro Oncol; 2023 Dec; 25(12):2287-2301. PubMed ID: 37486991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of H3K27 Trimethylation Promotes Radiotherapy Resistance in Medulloblastoma and Induces an Actionable Vulnerability to BET Inhibition.
    Gabriel N; Balaji K; Jayachandran K; Inkman M; Zhang J; Dahiya S; Goldstein M
    Cancer Res; 2022 May; 82(10):2019-2030. PubMed ID: 35315927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma.
    Cheng Y; Liao S; Xu G; Hu J; Guo D; Du F; Contreras A; Cai KQ; Peri S; Wang Y; Corney DC; Noronha AM; Chau LQ; Zhou G; Wiest DL; Bellacosa A; Wechsler-Reya RJ; Zhao Y; Yang ZJ
    Cell Rep; 2020 Jun; 31(12):107782. PubMed ID: 32579914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal miR-101-3p and miR-423-5p inhibit medulloblastoma tumorigenesis through targeting FOXP4 and EZH2.
    Xue P; Huang S; Han X; Zhang C; Yang L; Xiao W; Fu J; Li H; Zhou Y
    Cell Death Differ; 2022 Jan; 29(1):82-95. PubMed ID: 34294888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
    von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
    BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H6 enhances F-actin rearrangement by targeting c-MYC activation to promote medulloblastoma migration and invasion.
    Fan J; Wang Y; Liang X; Peng Y; Li S; Li X; Zhou F; Li Y
    Med Oncol; 2023 Jan; 40(3):85. PubMed ID: 36692844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
    Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
    Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
    J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
    Lau KM; Chan QK; Pang JC; Ma FM; Li KK; Yeung WW; Cheng AS; Feng H; Chung NY; Li HM; Zhou L; Wang Y; Mao Y; Ng HK
    Acta Neuropathol; 2012 Apr; 123(4):553-71. PubMed ID: 22249617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.